$ cat ./records/gates-foundation-awards-35-million-extension-to-target-malaria-fo-2016.txt
Gates Foundation awards $35 million extension to Target Malaria for gene drive mosquito development
[RECORD.TXT] · cat --full
The Gates Foundation provided a $35 million funding extension to Target Malaria, covering three and a half years of continued gene drive research and field preparation. The funding supported development of a 'doublesex' gene drive strain at Imperial College London that, in cage trials, caused population collapse with no emergence of resistance — a critical proof of concept. It also funded community engagement programs across Burkina Faso, Mali, and Uganda, and preparation of regulatory dossiers for the first field releases of modified mosquitoes in Africa.
Source: https://gcgh.grandchallenges.org/case-study/gene-drive
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation awarded a grant to the International Rescue Committee for global humanitarian and refugee health programs
Next →
Breakthrough Energy Ventures Backs Apeel Sciences — Plant-Based Seed-Coat Technology That Extends Produce Shelf Life
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.